SVB Leerink Equities Analysts Lower Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) – Research analysts at SVB Leerink cut their FY2024 EPS estimates for shares of Fusion Pharmaceuticals in a note issued to investors on Monday, May 22nd. SVB Leerink analyst F. Khurshid now forecasts that the company will post earnings of ($1.59) per share for the year, down from their previous forecast of ($1.45). The consensus estimate for Fusion Pharmaceuticals’ current full-year earnings is ($1.77) per share.

A number of other brokerages have also commented on FUSN. Morgan Stanley cut their price objective on shares of Fusion Pharmaceuticals from $19.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, January 27th. Brookline Capital Management reiterated a “buy” rating on shares of Fusion Pharmaceuticals in a report on Monday, February 13th. Finally, B. Riley restated a “buy” rating and issued a $10.00 target price on shares of Fusion Pharmaceuticals in a research note on Thursday, March 30th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $8.67.

Fusion Pharmaceuticals Stock Down 1.2 %

Shares of Fusion Pharmaceuticals stock opened at $4.25 on Wednesday. The company has a fifty day moving average price of $4.05 and a 200 day moving average price of $3.57. The company has a current ratio of 12.73, a quick ratio of 12.73 and a debt-to-equity ratio of 0.17. Fusion Pharmaceuticals has a twelve month low of $1.98 and a twelve month high of $5.22. The stock has a market cap of $271.35 million, a price-to-earnings ratio of -2.14 and a beta of -1.14.

Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) last announced its quarterly earnings results on Thursday, March 16th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.02. Fusion Pharmaceuticals had a negative net margin of 10,176.33% and a negative return on equity of 49.39%. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FUSN. Perceptive Advisors LLC bought a new position in Fusion Pharmaceuticals in the 1st quarter worth about $10,405,000. Federated Hermes Inc. grew its position in Fusion Pharmaceuticals by 81.4% in the 1st quarter. Federated Hermes Inc. now owns 5,849,100 shares of the company’s stock worth $22,051,000 after purchasing an additional 2,625,000 shares during the last quarter. Braidwell LP bought a new position in shares of Fusion Pharmaceuticals in the fourth quarter valued at approximately $6,300,000. FMR LLC boosted its holdings in shares of Fusion Pharmaceuticals by 73.9% in the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock valued at $17,649,000 after acquiring an additional 1,989,403 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in shares of Fusion Pharmaceuticals in the first quarter valued at approximately $4,839,000. Institutional investors own 59.39% of the company’s stock.

About Fusion Pharmaceuticals

(Get Rating)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.